|
| Press Releases |
|
 |
|
| Wednesday, June 15, 2022 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, June 9, 2022 |
|
|
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE |
| SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA). more info >> |
|
| Wednesday, April 20, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Monday, February 7, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Tuesday, November 30, 2021 |
|
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03 |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 26, 2021 |
|
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Over 80,000 international buyers at HKTDC's first three trade fairs in 2025
Jan 9, 2025 22:45 HKT/SGT
|
|
|
Education & Careers Expo opens next Thursday 
Jan 9, 2025 22:40 HKT/SGT
|
|
|
Strengthening Supply Chains for a Sustainable Future
Jan 9, 2025 22:30 HKT/SGT
|
|
|
'Think Business, Think Hong Kong' opened doors to more fruitful, sustainable Hong Kong-Indonesia partnership
Jan 9, 2025 22:20 HKT/SGT
|
|
|
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 9, 2025 21:34 HKT/SGT
|
|
|
CONTIOCEAN OFFICIALLY LISTED ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE
Jan 9, 2025 19:56 HKT/SGT
|
|
|
Stableton, Swiss Leader in VC Direct Secondaries, Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 9, 2025 15:30 HKT/SGT
|
|
|
Ho Chi Minh to Host Asia's Longest Running Sustainability Event - The 17th Annual Global CSR & ESG Summit and Awards 2025
Jan 9, 2025 15:17 HKT/SGT
|
|
|
Sparkline Hosts Exclusive Webinar on Leveraging Google Analytics 4 for E-Commerce Success
Jan 9, 2025 13:00 HKT/SGT
|
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 9, 2025 08:00 HKT/SGT
|
|
|
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 8, 2025 22:30 HKT/SGT
|
|
|
'Behind the Canvas Series 1: Jean-Michel Basquiat' Makes Its Global Debut in Singapore
Jan 8, 2025 17:00 HKT/SGT
|
|
|
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 8, 2025 17:32 JST
|
|
|
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 8, 2025 12:30 JST
|
|
|
The Quantum Revolution. How Quantum Computing Will Transform the Global Economy in the Next Decade
Jan 8, 2025 08:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
